scispace - formally typeset
L

Laura M. Kuyper

Researcher at University of British Columbia

Publications -  23
Citations -  1552

Laura M. Kuyper is an academic researcher from University of British Columbia. The author has contributed to research in topics: Atenolol & Blood pressure. The author has an hindex of 13, co-authored 22 publications receiving 1175 citations. Previous affiliations of Laura M. Kuyper include Vancouver General Hospital & St. Paul's Hospital.

Papers
More filters
Journal ArticleDOI

Hypertension Canada’s 2018 Guidelines for Diagnosis, Risk Assessment, Prevention, and Treatment of Hypertension in Adults and Children

Kara Nerenberg, +82 more
TL;DR: All individuals with hypertension should have an assessment of global cardiovascular risk to promote health behaviours that lower blood pressure, and an angiotensin receptor-neprilysin inhibitor combination should be used in place of either an ang Elliotensin-converting enzyme inhibitor or angiotENSin receptor blocker in individuals with heart failure.
Journal ArticleDOI

Hypertension Canada's 2020 Comprehensive Guidelines for the Prevention, Diagnosis, Risk Assessment, and Treatment of Hypertension in Adults and Children.

Doreen M. Rabi, +81 more
TL;DR: The 2020 guidelines include new guidance on themanagement of resistant hypertension and the management of hypertension in women planning pregnancy.
Journal ArticleDOI

Characterization of airway plugging in fatal asthma.

TL;DR: Airway lumenal obstruction by an exudate composed of mucus and cells is a major contributing cause of fatal asthma in most patients.
Journal ArticleDOI

Unstable housing, associated risk behaviour, and increased risk for HIV infection among injection drug users

TL;DR: It is suggested that unstable housing environments are associated with elevated risk of HIV- infection due to risk behaviours that take place in these environments.
Journal ArticleDOI

Atenolol vs Nonatenolol β-Blockers for the Treatment of Hypertension: A Meta-analysis

TL;DR: In the young, both atenolol and nonatenolol β-blockers are effective in reducing cardiovascular end points for hypertension without compelling indications.